RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies
Sponsor: CervoMed, Inc
A PHASE2 clinical study on Dementia With Lewy Bodies, this trial is completed. The trial is conducted by CervoMed, Inc and has accumulated 15 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 10 earlier versions
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE2
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CervoMed, Inc
- EIP Pharma Inc
- National Institute on Aging (NIA)
- Worldwide Clinical Trials
For direct contact, visit the study record on ClinicalTrials.gov .